Sosei Heptares (the corporate brand of Sosei Group Corporation) is a research-focused biotechnology group, publicly listed in Japan (TSE: 4565) and with sites in Tokyo, London and Cambridge (UK).

Our mission is to make a significant contribution to improving the quality of life and health of people around the world. To achieve this, we will discover, design and develop the most innovative and effective medicines for patients worldwide, through our world-leading patent-protected technology and platform.

Our primary focus is the discovery and early development of new medicines originating from its proprietary G Protein-Coupled Receptor (GPCR)-targeted StaR® technology and Structure-Based Drug Design (SBDD) platform capabilities. The company is advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including CNS, immuno-oncology, gastroenterology, inflammation and other rare/specialty indications.

Our Company has established partnerships with some of the world’s leading pharmaceutical companies, including AbbVie, AstraZeneca, Biohaven, Genentech (Roche), GSK, Novartis, Pfizer and Takeda and additionally with multiple emerging technology companies. Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&D facilities in Cambridge, UK.

Sosei Heptares has approximately 148 employees based at its new R&D research facility at Granta Park. The size of the company ensures a transparent linkage between all activities from early discovery through to clinical development.

We are currently looking to strengthen our Molecular Pharmacology team and are now seeking to recruit a highly motivated, experienced Principal Scientist to join our team. The Molecular Pharmacology team is responsible for supporting targets from Target Validation through to Candidate Nomination.

Main tasks will include:

• Project management
• Developing robust in vitro assays to support Hit ID
• Routine screening, data upload and QC of results in internal databases
• Working with primary cell assays to help establish Target Engagement and Biomarkers assays to support compound progression
• Mentoring others (may have direct line management responsibilities)
• Initiation and management of studies at Contract Research Organisations
• Regular communication and interaction with external research partners
• Technical and strategic input to in area of expertise

• Extensive experience working within a collaborative, multi-disciplinary, pharmaceutical/biotech environment with a track record of scientific achievements and contributions.
• Proven project management experience (effective project management skills)
• Therapeutic expertise within the areas of immunology or neuroscience
• Ability to work flexibly within a team, whilst being highly self-motivated and able to work independently
• Analytical thinking and good problem-solving skills
• Excellent organisational and time-management skills, as well as the ability to work to strict deadlines
• The ability to communicate clearly, both verbally and in written reports, in English.

Also desirable but not essential includes:

• Previous experience with GPCRs
• Previous line management responsibilities.

The successful candidate will be employed by Heptares Therapeutics Ltd, a UK wholly owned subsidiary of Sosei Group Corporation.

We offer a competitive salary, commensurate with qualifications and experience, and benefits package including pension and healthcare schemes.

Applications should include a covering letter, providing a short description of the background to their interest in the role, with curriculum vitae including the names and contact details for two referees. Please apply through our on-line jobs portal with your application in pdf format, quoting reference number 2020-2MP.

Sosei Heptares does not accept speculative or unsolicited CVs from agencies. All speculative or unsolicited CVs submitted without an agreement in place will be considered Sosei Heptares's property and will not obligate us to pay a referral fee.

The closing date for applications is 31st July 2021.